Drug Trial Radar · NCT03412799
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: May 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jun 4, 2018
Primary completion
Feb 28, 2022
Study completion Feb 28, 2022
Sponsor
- Lead sponsor
- Panbela Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.
Conditions
- Pancreatic Cancer Metastatic
- Pancreatic Cancer Stage IV
- Stage IV Pancreatic Cancer
Interventions
SBP-101Drug
Administered as subcutaneous (SC) injection, escalating dose cohorts
nab-paclitaxelDrug
Administered as intravenous (IV) infusion
Gemcitabine InjectionDrug
Administered as intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended dose of SBP-101Time frame: Up to 12 months following the first dose of treatment
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Scripps MD Anderson Cancer Center
La Jolla, California
University of Florida
Gainesville, Florida
University of Rochester Medical Center
Rochester, New York
Blacktown Cancer & Haematology Centre
Blacktown, New South Wales, Australia
John Flynn Private Hospital
Tugun, Queensland, Australia
Ashford Cancer Centre
Kurralta Park, South Australia, Australia
Austin Health
Heidelberg, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.